Physician profile
Suyin Chi
NPI 1346482874
$2,557.44
in general payments reported to CMS, 2019-2025
16 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,428 · 2020: $151 · 2021: $255 · 2022: $165 · 2024: $456 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $558.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,120.61 | 2019-2025 | Dovato, Rukobia, Cabenuva |
| Janssen Products, Lp | $328.48 | 2019 | |
| Janssen Biotech, INC. | $255.70 | 2019-2022 | |
| Theratechnologies INC. | $198.36 | 2019 | |
| Gilead Sciences, INC. | $153.68 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $118.32 | 2019-2021 | |
| Emd Serono, INC. | $115.15 | 2024 | Serostim |
| Napo Pharmaceuticals INC | $84.26 | 2019-2022 | |
| Tetraphase Pharmaceuticals, INC. | $44.48 | 2019-2020 | |
| Allergan, INC. | $43.74 | 2019 | |
| La Jolla Pharmaceutical Company | $21.21 | 2022 | |
| Vyera Pharmaceuticals, LLC | $17.00 | 2019 | |
| Philips North America LLC | $15.06 | 2019 | |
| Abbvie INC. | $14.35 | 2022 | |
| Mayne Pharma Commercial LLC | $13.69 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $13.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suyin Chi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.